Local neuroinflammation and the progression of Alzheimer's disease

Journal of NeuroVirology

Volumn 8, Issue 6, 2002, Pages 529-538

  McGeer, Patrick L ^a   McGeer, Edith G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chemokines; Complement; Cytokines; Microglia; NSAIDs; Pentraxins

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ARTHROTEC; C REACTIVE PROTEIN; CHEMOKINE; COLONY STIMULATING FACTOR; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4B; COMPLEMENT INHIBITOR; COMPSTATIN; CYCLOOXYGENASE 2; CYTOKINE; DICLOFENAC; INDOMETACIN; MEMBRANE COFACTOR PROTEIN; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PENTRAXIN; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; QUINOLINOL DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; AUTOPSY; BRAIN TISSUE; CELL ACTIVATION; CHRONIC INFLAMMATION; CLINICAL TRIAL; COMPLEMENT SYSTEM; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG EFFICACY; DRUG TARGETING; EPIDEMIOLOGY; HEART INFARCTION; HOST; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOHISTOCHEMISTRY; INTERSTITIAL CYSTITIS; MACROPHAGE; MICROGLIA; MITOSIS; NERVE CELL; OTOTOXICITY; PHYLOGENY; PRIORITY JOURNAL; RETINA INJURY; REVIEW; TISSUE DEGENERATION;

ALZHEIMER DISEASE; DISEASE PROGRESSION; ENCEPHALITIS; HUMANS; NEUROIMMUNOMODULATION;

EID: 0036949091     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.1080/13550280290100969     Document Type: Review

References (84)

1. Aisen PS, Davis KL, et al (2000). A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 54: 588-593.
2. Akiyama H, Yamada T, et al (1991). Association of amyloid P component with complement proteins in neurologically diseased tissue. Brain Res 548: 349-352.
3. Alldred A (2001). Etanercept in rheumatoid arthritis. Exp Opin Pharmacother 1: 1137-1148.
4. Asensio VC, Campbell IL (1999). Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci 22: 504-512.
5. Bacon KB, Harrison JK (2000). Chemokines and their receptors in neurobiology: perspectives in physiology and homeostasis. J Neuroimmunol 104: 92-97.
6. Baik EJ, Kim EJ, et al (1999). Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res 843: 118-129.
7. Blacker D, Wilcox MA, et al (1998). Alpha-2-macroglobulin is genetically associated with Alzheimer's disease. Nat Genet 19: 357-360.
8. Broe GA, Grayson DA, et al (2000). Anti-inflammatory drugs protect against Alzheimer's disease at low doses. Arch Neurol 57: 1586-1591.
9. Cacebelos R, Alvarez XA, et al (1994). Brain interleukin-1 beta in Alzheimer's disease and vascular dementia. Methods Find Exp Clin Pharmacol 16: 141-145.
10. Chapman GA, Moores K, et al (2000). Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci 20: 2-6.
11. Collin JS, Perry RT, et al (2000). Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer's disease: the NIMH Alzheimer's disease genetics initiative. Am J Med Genet 96: 823-830.
12. Dickson DW, Lee SC, et al (1993). Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7: 75-83.
13. Du Y, Dodel RC, et al (2000). Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology 55: 480-483.
14. Eikelenboom P, Hack CE, et al (1989). Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch Cell Pathol 56: 259-262.
15. Ferreira SH, Moncada S, Vane JR (1973). Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Brit J Pharmacol 49: 86-97.
16. Fiane AE, Mollnes TE, et al (1999). Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation 6: 52-65.
17. Furlong ST, Dutta AS, et al (2000). C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles. Immunopharmacology 48: 199-212.
18. Griffin WST, Stanley LC, et al (1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease. Proc Soc Natl Acad Sci USA 86: 7611-7615.
19. Grimaldi LM, Casadei VM, et al (2000). Association of early-onset Alzheimer's disease with an interleukin-1α gene polymorphism. Ann Neurol 47: 361-365.
20. Hamilton K, Clair EW (2000). Tumour necrosis factor-alpha blockade: a new era for the effective management of rheumatoid arthritis. Exp Opin Pharmacother 1: 1041-1052.
21. Haymaker W, Adams RD (eds) (1982). Histology and histopathology of the nervous system. Charles C Thomas: Springfield, IL, pp 1150-1173.
22. Hesselgesser J, Horuk R (1999). Chemokine and chemokine receptor expression in the central nervous system. J Neurovirol 5: 13-26.
23. Hicks PS, Saunero-Nazia L, et al (1992). Serum amyloid P component binds to histones and activates the classical complement pathway. J Immunol 149: 3689-3694.
24. Hope HR, Remsen EE, et al (2000). Large-scale purification of myeloperoxidase from KL60 promyelocytic cells: characterization and comparison to human neutrophil myeloperoxidase. Protein Expr Purif 18: 269-276.
25. Ishii T, Haga S (1984). Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques. Acta Neuropathol (Berlin) 63: 296-300.
26. Itagaki S, Akiyama H, et al (1994). Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res 645: 78-84.
27. Jiang H, Robey F, et al (1992). Localization of sites through which C-reactive protein binds to and activates complement to residues 14-26 and 76-92 of the human C1q A chain. J Exp Med 175: 1373-1379.
28. Kamboh MI, Aston CE, et al (1997). Genetic effect of alpha-1-antichymotrypsin on the risk of Alzheimer's disease. Genomics 40: 382-384.
29. Kaufmann WE, Worley PF, et al (1996). COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at post-synaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 93: 2317-2321.
30. Klegeris A, McGeer PL (2000). Interaction of various intracellular signaling mechanisms involved in mononuclear phagocyte toxicity toward neuronal cells. J Leukoc Biol 67: 127-133.
31. Klegeris A, Walker DG, et al (1999). Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs). Neuropharmacology 38: 1017-1025.
32. Lagrand WK, Visser CA, et al (1999). C-reactive protein as a cardiovascular risk factor. Circulation 100: 96-102.
33. Lambris DH (1993). The chemistry, biology, and phylogeny of C3. In: Complement today. Cruise JM, LLewis RE Jr (eds). Karger: Basel, pp 16-45.
34. Licastro F, Pedrini S, et al (2000a). Polymorphisms of the IL-6 gene increase the risk for late onset Alzheimer's disease and affect IL-6 plasma levels. Neurobiol Aging 21(1S): S38.
35. Licastro F, Pedrini S, et al (2000b). Gene polymorphism affecting α1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol 48: 388-391.
36. Lieberman AP, Pitha PM, et al (1989). Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci USA 86: 6348-6352.
37. MacKenzie IRA (2000). Anti-inflammatory drugs and Alzheimer-type pathology in aging. Neurology 54: 732-734.
38. McCusker SM (2001). Association between polymorphism in regulatory region of gene encoding tumour necrosis factor A and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet 357: 436-439.
39. McGeer EG, Yasojima K, et al (2001). Inflammation in the pathogenesis of Parkinson's disease. BC Med J 43: 138-141.
40. McGeer PL (2000). Cyclooxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging 17: 1-11.
41. McGeer PL, Akiyama H, et al (1989). Immune system response in Alzheimer's disease. Can J Neurol Sci 16: 516-527.
42. McGeer PL, Harada N, et al (1992). Prevalence of dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug therapy. Dementia 3: 146-149.
43. McGeer PL, McGeer EG (1995). The inflammatory response system of brain: implications for therapy of Alzheimer's and other neurodegenerative diseases. Brain Res Rev 21: 195-218.
44. McGeer PL, McGeer EG (2000). Autotoxicity and Alzheimer's disease. Arch Neurol 57: 789-790.
45. McGeer PL, McGeer EG (2001). Polymorphisms in inflammatory genes enhance the risk of Alzheimer's disease. Arch Neurol 58: 1790-1792.
46. McGeer PL, Rogers J, et al (1990). Anti-inflammatory drugs and Alzheimer's disease? Lancet 335, 1037.
47. McGeer PL, Schulzer M, et al (1996). Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 47: 425-432.
48. Muir KW, Weir CJ, et al (1999). C-reactive protein and outcome after ischemic stroke. Stroke 30: 981-985.
49. Nakayama M, Uchimura K, et al (1998). Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci USA 95: 10954-10959.
50. Neuroinflammation Working Group (2000). Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
51. Nicoll JAR, Mrak RE, et al (2000). Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 47: 365-368.
52. Papassotiropoulos A, Bagli M, et al (1999). A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann Neurol 45: 666-668.
53. Pietila KO, Harmoinen AP, et al (1996). Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 17: 1345-1349.
54. Rebeck GW (2000). Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease. Neurosci Lett 293: 75-77.
55. Reynolds WF, Rhees J, et al (1999). Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 155: 31-41.
56. Ridker PM, Hennekens CH, et al (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843.
57. Rogers J, Cooper NR, et al (1992). Complement activation by β-amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 89: 10016-10020.
58. Rogers J, Kirby LC, et al (1993). Clinical trial of indomethacin in Alzheimer's disease. Neurology 43: 1609-1611.
59. Sainati SM, Ingram DM, et al (2000). Results of a double-blind, placebo-controlled study of celecoxib for the progression of Alzheimer's disease. In: Proceedings of 6th International Stockholm-Springfield Symposium of Advances in Alzheimer's Therapy. p 180.
60. Scharf S, Mander A, et al (1999). A double-blind, placebo-controlled trial of diclofenac misoprostol in Alzheimer's disease. Neurology 53: 197-201.
61. Schwartz CF, Kilgore KS, et al (1999). Increased rat cardiac allograft survival by the glycosaminoglycan pentosan polysulfate. J Surg Res 86: 24-28.
62. Sharif SF, Hariri RJ, et al (1993). Human astrocyte production of tumour necrosis factor-alpha, interleukin-1 beta, and interleukin-6 following exposure to lipopolysaccharide endotoxin. Neurol Res 15: 109-112.
63. Stewart WF, Kawas C, et al (1997). Risk of Alzheimer's disease and duration of NSAID use. Neurology 48: 626-632.
64. Strittmatter WJ, Saunders A, et al (1993). Apolipoprotein E: high avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 90: 1977-1981.
65. Tanhehco EJ, Kilgore KS, et al (1999). Reduction of myocardial infarct size after ischemia and reperfusion by the glycosaminoglycan pentosan polysulfate. J Cardiovasc Pharmacol 34: 153-161.
66. Van Gool WA, Weinstein HC, et al (2001). Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomized, double-blind, placebo-controlled study. Lancet 358: 455-460.
67. Veld BAI, Ruitenberg A, et al (2000). Duration of non-steroidal antiinflammatory drug use and risk of Alzheimer's disease. The Rotterdam study. Neurobiol Aging 21(1S): S204.
68. Veld BAI Ruitenberg A, et al (2001). Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. New Engl J Med 345: 1515-1521.
69. Walker DG, Kim SU, et al (1995). Complement and cytokine gene expression in cultured microglia derived from postmortem human brains. J Neurosci Res 40: 478-493.
70. Wallace JL, Pittman QJ, et al (1995). Nitric oxide-releasing NSAIDs: a novel class of GI-sparing anti-inflammatory drugs. Agents Actions 46(Suppl): 121-129.
71. Webster S, Bonnell B, et al (1997a). Charge-based binding of complement component C1q to the Alzheimer's amyloid beta-peptide. Am J Pathol 150: 1531-1536.
72. Webster S, Lue LF, et al (1997b). Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging 18: 415-421.
73. Wood JA, Wood PL, et al (1993). Cytokine indices in Alzheimer's temporal cortex: no change in mature IL beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res 629: 245-252.
74. Xia MQ, Qin SX, et al (1998). Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol 153: 31-37.
75. Yamabe T, Dhir G, et al (1994). Cytokine-gene expression in measles-infected adult human glial cells. J Neuroimmunol 49: 171-179.
76. Yasojima K, McGeer EG, et al (1999a). Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer's disease. Brain Res 633: 297-301.
77. Yasojima K, Schwab C, et al (1998). Human heart generates complement proteins that are upregulated and activated after myocardial infarction. Circ Res 83: 860-869.
78. Yasojima K, Schwab C, et al (1999b). Upregulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol 154: 927-936.
79. Yasojima K, Schwab C, et al (1999c). Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 830: 226-236.
80. Yasojima K, Schwab C, et al (2000). Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 867: 80-89.
81. Yasojima K, Schwab C, et al (2001). Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158: 1039-1051.
82. Ying SC, Gewurz AT, et al (1993). Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q. J Immunol 150: 169-176.
83. Zlotnik A, Yoshie O (2000). Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127.
84. Zujovic V, Benavides J, et al (2000). Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activator. Glia 29: 305-315.